Where We
Are Headed

The Past & Future Of Psychedelics As Medicine

Coming soon as a book

We Are

The Past &
Future Of
As Medicine

We Are

The Past &
Future Of
As Medicine


For thousands of years, psychedelic compounds
have been a part of different ethnic and social
cultures around the world.

Today, they are transforming healthcare.


Psychedelics (sometimes known as entheogens) are substances that alter consciousness in various ways.

When taken in large enough doses, psychedelics induce what is commonly referred to as an altered state of consciousness, characterized by radically changed perceptions, intense emotions and novel thoughts.

Psychedelics can be naturally derived or synthetically produced.


The use of psychedelics extends back through a number of ancient cultures.

Organic residues of the psychoactive compound DMT were recently discovered in a 1000 year-old pouch from the South American Andes.
years ago
(Tap images to see their captions.)
(Hover over images to see their captions.)
This small ritual container, made of three fox snouts, contains the earliest known evidence of ayahuasca preparation.
Other indigenous groups from around the world have also used psychedelics for sacred and ceremonial purposes across history.

This includes groups in West Africa (using Ibogaine), the Greeks (Ergot fungus), Hindus (Amanita Muscaria), Native Americans (Peyote/Mescaline), and likely many more.


Swiss chemist Albert Hofmann discovered that a chemical he had synthesized years before induced a dreamlike psychedelic state. That compound was LSD.


Fast forward to
On April 16th, 1943 Albert Hofmann accidentally absorbed LSD through his fingertips while conducting research in his lab. He became intoxicated and decided to go home, where he lay down and closed his eyes, only to see "an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors".

On April 19th Hofmann intentionally ingested 250 micrograms of LSD to learn more about the compound.

He decided to ride his bicycle home from his laboratory, during which time he experienced the intense and profound effects of the compound.

Hofmann became severely anxious and believed he was dying, but when he arrived home his physician visited him and declared him to be perfectly healthy.

When he recovered from his experiment, he felt that LSD would eventually be used in a clinical sense as a psychiatric tool.

This important day in psychedelic history is now known as "bicycle day".
...there were over 1000 scientific papers on medical and psychotherapeutic research with psychedelics.

These papers highlighted that psychedelics had a number of legitimate use cases, including helping people overcoming alcoholism, reforming prisoners, and and also for self-experimentation by psychiatrists, “to gain an insight into the world of ideas and sensations of mental patients".





Robert Wasson, the Vice President for Public Relations at J.P. Morgan & Co, and his wife, are the first westerners to be allowed to participate in a Mazatec psilocybin mushroom ritual ceremony led by curandera Maria Sabina.

The following year, LIFE Magazine published an article by Wasson titled "Seeking the Magic Mushroom", which introduced psychoactive mushrooms to a wide audience for the first time in history.


Swiss chemist Albert Hofmann identifies and isolates psilocybin for the first time from samples sent by Robert Wasson to him.

Later, they traveled together to Mexico to give Marina Sabina a capsule of psilocybin for her to identify if he had successfully isolated "the spirit of the mushroom", and she agreed they had.


The Harvard psilocybin project began.

167 test subjects, along with the lead researchers (above) consumed various doses of psilocybin across a number of sessions.

‍This study led to the conclusions that, while 75% of the subjects in general described their trip as pleasant, 69% were considered to have reached a marked broadening of awareness

At the end of the study, 95% of the subjects declared that the psilocybin experience had "changed their lives for the better".
Researchers Richard Alpert (AKA Ram Dass, left) and Timothy Leary (right) of Harvard University.

A still from Dying To Know: Ram Dass & Timothy Leary, a film by Gay Dillingham.


Walter Pahnke's "Good Friday" experiment

On good Friday, 1962, before services commenced in Boston University's Marsh Chapel, Pahnke administered small capsules to twenty Protestant divinity students.

Thus began the most scientific experiment in the literature designed to investigate the potential of psychedelic drugs to facilitate mystical experience.

Half the capsules contained psilocybin (30mg)... and the other half contained a placebo.

According to Pahnke, the experiment determined that "the persons who received psilocybin experienced to a greater extent than did the controls the phenomena described by our typology of mysicism."

- Excerpt from Rick Doblin (founder of MAPS)' undergraduate thesis (1978)


The Spring Grove Experiments Begin

Researchers from the Spring Grove clinic in Maryland began using LSD to treat over 700 people with psychotic illnesses.

The research successfully demonstrated that LSD can be used to treat narcotic addiction and alcoholism, showing abstinence data "significantly in favor of the treatment group".
...some 40,000 patients had been prescribed some form of LSD therapy as treatment for a wide range of clinical conditions including neurosis, schizophrenia, autism, and psychopathy.


Within a few decades of Hofmann's discovery, LSD became a defining element of the 1960’s countercultural movement, encapsulated by the notorious phrase "Turn on, tune in, drop out".


Then come the


Despite strong opposition from psycholists and scientists, LSD was made illegal in the United states and was designated by the federal government as a drug with a “high potential for abuse” and one without any “currently accepted medical use in treatment.”


Many other countries, including Canada and most of Europe followed when the UN Convention on Psychotropic Substances was adopted, effectively banning all psychedelics and psychedelic research in most parts of the world.
The Nixon Government launched the "War on Drugs" in 1971.
This "war" also unfairly targeted a number of ethnic and racial groups.
Since it began in 1971, it has cost America over $1 trillion.
Incarceration rates have skyrocketed as a result of the "war".
Nixon's War On Drugs marked the beginning of a “psychedelic winter”, which effectively ended all public research efforts towards discovering the therapeutic and medicinal properties of psychedelics for several decades.




Rick Strassman's study with DMT

After decades of prohibition, Strassman receives permission to inject 12 human participants with DMT...

"Subjects were carefully interviewed after resolution of drug effects, providing thorough and systematic descriptions of DMT's effects.

Hallucinogenic effects... included a rapidly moving, brightly colored visual display of images. "Loss of control," associated with a brief, but overwhelming "rush," led to a dissociated state, where euphoria alternated or coexisted with anxiety.

These effects completely replaced subjects' previously ongoing mental experience and were more vivid and compelling than dreams or waking awareness."
After many years of prohibition, recent discoveries have again begun to demonstrate immense possibility for psychedelics as medicines, especially in the context of helping people with mental health issues.




Mental health is a growing and global problem.

Research suggests that 971 million people, or roughly 13% of the global population suffer from some form of mental disorder.
154 million
45 million
Eating Disorders
15 million
322 million
300 million
264 million
164 million
20 million
While treatments exist for these disorders, they are frequently ineffective, difficult to access, or too expensive for most people. Many current pharmaceutical treatments can also have severe negative side effects.

Furthermore, despite progress towards destigmatization, many people have difficulty seeking help for their mental health. As a result their conditions often become worse while they remain silent.




Over the past few years a number of compelling findings have led to a re-evaluation of the current narrative around psychedelics.

Increasingly, they are being recognized as powerful tools for tackling severe health problems, especially those that concern the brain.
Research led by Roland Griffiths at John Hopkins University demonstrates that under supportive conditions, psilocybin can induce profound positive experiences, and can even induce lasting personality changes.


Researchers from Arizona demonstrate that psilocybin can be used to acutely reduce symptoms of obsessive-compulsive disorder.


Norwegian researchers conduct a meta-analysis of research conducted pre-prohitition, showing strong evidence for the effectiveness of treating alcoholism with LSD.


Mounting evidence highlights that through various methods of delivery, ketamine can be used to significantly reduce symptoms of treatment-resistant depression.


MDMA-assisted psychotherapy is shown to be as effective in helping patients with treatment-resistant post-traumatic stress disorder.


Research led by Imperial College of London reveals how consciousness is altered and how the brain behaves differently under the influence of psilocybin.

This research included evidence that psychedelics reduce activity in the default-mode network, a part of the brain that is responsible for self-representation (ego).


Images from Imperial College of London's research on how psychedelics effect the brain. These connections highlight that under the influence of psilocybin, different regions of the brain become more connected (ie. communicate with one another) than they would in the context of normal consciousness.
Research from Johns Hopkins University shows that psilocybin can help people quit smoking more effectively than existing treatments.


In January 2015, MDMA-assisted therapy was notably featured on the front page of the British Journal of Psychiatry.
Researchers from University of New Mexico and Brazil find that psilocybin-enhanced therapy is highly effective for overcoming alcohol dependence.


A study of 190,000 Americans shows that lifetime psychedelic use was associated with significantly reduced odds of psychological distress and suicidality.


Research from Johns Hopkins University shows that psilocybin treatment significantly reduces end-of-life anxiety and depression in late-stage cancer patients.


The "living room" in the Johns Hopkins Psychedelic Research Unit is where psilocybin research sessions take place. The room is intended to be a comfortable, aesthetic environment free of unnecessary medical or research equipment.
Researchers from NYU demonstrate that Ibogaine is highly effective for helping people overcome opioid addictions and withdrawal symptoms.


Researchers demonstrate Ayahuasca creates clinical improvements lasting over 6 months in people with psychiatric disorders.


After decades of thorough and credible research, psychedelic substances are finally becoming approved for clinical trials and use in popular medicine.


The American Food and Drug Agency (FDA) grants The Multidisciplinary Association for Psychedelic Studies (MAPS) breakthrough therapy designation for MDMA-assisted psychotherapy for the treatment of PTSD.


FDA grants Compass Pathways breakthrough therapy status for psilocybin for treating treatment-resistant depression.


FDA gives Janssen Pharmaceuticals approval to begin selling (Sprovado) esketamine as a treatment for for treatment-resistant depression.


Usona Institute receives FDA breakthrough therapy status for psilocybin to treat major depressive disorder.


MAPS announces results from phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD, showing a 90% chance of there being a statistically significant difference in symptoms after treatment.


While psychedelic medicines are already benefiting patients with serious mental health problems, we are still just beginning to discover their full potential.


At Mindleap Health, we are committed to upgrading mental healthcare and to being a responsible member of the psychedelic community. Our platform connects people with psychedelic integration specialists, addiction coaches, and tools for mental health management.

Visit our website to learn more.

If you'd like to offer your psychedelic integration services on our platform, email us here.